Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Crown Castle International Corp (CCI) Price & Performance

Bristol-Myers Squibb CoTrade
Crown Castle International CorpTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Crown Castle International Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.94 (market cap $129.94B), while Crown Castle International Corp trades at $74.34 (market cap $31.33B). The key difference: Bristol-Myers Squibb Co is far larger — about 4.1× Crown Castle International Corp's market cap, and Crown Castle International Corp pays the higher dividend (5.77%). Which is the better fit depends on your goals.

BMYCCI
Market Cap
$129.94B$31.33B
Sector
HealthReal Estate
52-Week High
$65.89$103.79
52-Week Low
$42.60$73.61
Enterprise Value
$163.92B$53.69B
Dividend Yield
3.96%5.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.

The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.

Crown Castle International Corp

Crown Castle (CCI) trades at $73.61, down 2.62% on the day and near 52-week lows. The technical picture is bearish with mixed fundamentals - strong profitability margins (73.7% gross margin) but negative shareholder equity and high debt levels. Recent Q2 2026 earnings beat expectations with AFFO of $1.13 per share, while the company transitions to a pure-play U.S. tower operator following asset sales.

The stock presents a contrarian opportunity with 50% analyst buy ratings and a $95.29 price target suggesting 29% upside, but faces significant debt burden and execution risks from strategic shifts. The 5.5% dividend yield provides income support while investors await operational improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Crown Castle International Corp

Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.

Read more on CCI